Romaldini J H, Werner M C, Rodrigues H F, Teixeira V L, Werner R S, Farah C S, Bromberg N
J Endocrinol Invest. 1986 Jun;9(3):233-8. doi: 10.1007/BF03348107.
We studied the effects of high doses of methimazole (MMI) or propylthiouracil (PTU) on thyroid-stimulating antibody (TSAb), antithyroid microsomal (MCHA) and antithyroglobulin (TGHA) levels in Graves' disease and Hashimoto's thyroiditis. Thirty Graves' hyperthyroid patients were treated for 14 +/- 8 months (mean +/- SD) with MMI, 60-80 mg daily or PTU, 900-1200 mg daily plus T3, 50-75 micrograms daily. Fifteen Hashimoto's thyroiditis patients (4 of whom hypothyroid) received 100-200 micrograms of T4 daily for 4-8 weeks prior to MMI, 60-90 mg daily or PTU, 900 mg daily for 12-16 weeks. In Graves' disease a decrease (p less than 0.001) in TSAb activity (20/25 patients) was observed: before therapy, 0.424 +/- 0.506 pmoles/mg wet wt and at the end of treatment, 0.189 +/- 0.23 pmoles/mg wet wt. The MCHA titers also fell (18/26 patients) from 1:10,403 +/- 20,197 to 1:3,476 +/- 5,252 (p less than 0.01) and was associated with a decrease in free T4 values (1.23 +/- 0.69 vs. 0.51 +/- 0.36 ng/dl; p less than 0.01). A fall of MCHA titers in T4-treated Hashimoto's thyroiditis patients (1:10,416 +/- 25,576) was found when compared with the value before T4 (1:25,920 +/- 39,973; p less than 0.001). However, the titers of MCHA (1:13,280 +/- 25,992) did not change on MMI or PTU plus T4 treatment. The TGHA titers fell in a single patient. No alterations were observed in serum immunoglobulins. Serum concentrations of the complement factor C'3 remained higher (p less than 0.01) than normal values in both Graves' disease and Hashimoto's thyroiditis.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了高剂量甲巯咪唑(MMI)或丙硫氧嘧啶(PTU)对格雷夫斯病和桥本甲状腺炎患者甲状腺刺激抗体(TSAb)、抗甲状腺微粒体抗体(MCHA)及抗甲状腺球蛋白抗体(TGHA)水平的影响。30例格雷夫斯病甲亢患者接受MMI(每日60 - 80mg)或PTU(每日900 - 1200mg加每日50 - 75μg T3)治疗14±8个月(均值±标准差)。15例桥本甲状腺炎患者(其中4例为甲状腺功能减退)在接受MMI(每日60 - 90mg)或PTU(每日900mg)治疗12 - 16周前,先每日服用100 - 200μg T4 4 - 8周。在格雷夫斯病患者中,观察到TSAb活性下降(20/25例患者,p<0.001):治疗前为0.424±0.506pmoles/mg湿重,治疗结束时为0.189±0.23pmoles/mg湿重。MCHA滴度也下降(18/26例患者),从1:10,403±20,197降至1:3,476±5,252(p<0.01),且与游离T4值下降相关(1.23±0.69 vs. 0.51±0.36ng/dl;p<0.01)。与T4治疗前相比,T4治疗的桥本甲状腺炎患者MCHA滴度下降(1:10,416±25,576对比1:25,920±39,973;p<0.001)。然而,MMI或PTU加T4治疗后MCHA滴度(1:13,280±25,992)未改变。仅1例患者TGHA滴度下降。血清免疫球蛋白未见改变。在格雷夫斯病和桥本甲状腺炎患者中,补体因子C'3的血清浓度均高于正常值(p<0.01)。(摘要截断于250字)